Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma

American Journal of Clinical Pathology

Volumn 137, Issue 1, 2012, Pages 93-100

  Alapat, Daisy ^a   Coviello Malle, Jean ^a   Owens, Rebecca ^a   Qu, Pingping ^c   Barlogie, Bart ^b   Shaughnessy, John D ^b   Lorsbach, Robert B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CD200; Chronic lymphocytic leukemia; Flow cytometry; Mantle cell lymphoma; Plasma cell myeloma

Indexed keywords

CD200 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPHATIC LEUKEMIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR DIFFERENTIATION;

ANTIGENS, CD; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MULTIPLE MYELOMA; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855265260     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP59UORCYZEVQO     Document Type: Article

References (32)

1. McCaughan GW, Clark MJ, Hurst J, et al. The gene for MRC OX-2 membrane glycoprotein is localized on human chromosome 3. Immunogenetics. 1987;25:133-135. (Pubitemid 17004651)
2. Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23:285-290. (Pubitemid 34628770)
3. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171:3034-3046. (Pubitemid 37093527)
4. Shiratori I, Yamaguchi M, Suzukawa M, et al. Downregulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol. 2005;175:4441-4449. (Pubitemid 41361980)
5. Gorczynski RM. Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages. Eur J Immunol. 2001;31:2331-2337. (Pubitemid 32785351)
6. Jenmalm MC, Cherwinski H, Bowman EP, et al. Regulation of myeloid cell function through the CD200 receptor. J Immunol. 2006;176:191-199. (Pubitemid 43023263)
7. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290:1768-1771. (Pubitemid 32004808)
8. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A. 2006;103:1041-1046. (Pubitemid 43212218)
9. Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33:1212-1216.
10. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194- 4197.
11. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566- 568.
12. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
13. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284. (Pubitemid 46425864)
14. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028. (Pubitemid 44395016)
15. McKenna RW, Asplund SL, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry. Leuk Lymphoma. 2004;45:277-285. (Pubitemid 38181429)
16. Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: a review and update. Leuk Lymphoma. 2010;51:10-19.
17. Ho AK, Hill S, Preobrazhensky SN, et al. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias. Am J Clin Pathol. 2009;131:27-32.
18. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897. (Pubitemid 33108161)
19. Gao J, Peterson L, Nelson B, et al. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009;132:699-706.
20. D'Arena G, Dell'Olio M, Musto P, et al. Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. Leuk Lymphoma. 2001;42:649-654. (Pubitemid 32782771)
21. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009;23:1941-1956.
22. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-3967.
23. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724-1732. (Pubitemid 44316143)
24. Le Baccon P, Leroux D, Dascalescu C, et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer. 2001;32:250-264. (Pubitemid 32953979)
25. Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91:1732-1741. (Pubitemid 28110339)
26. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am J Clin Pathol. 2010;134:726-733.
27. Olteanu H, Harrington AM, Hari P, et al. CD200 expression in plasma cell myeloma. Br J Haematol. 2011;153:408-411.
28. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313-325.
29. Seegmiller AC, Kroft SH, Karandikar NJ, et al. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132:940-949.
30. Pui CH, Raimondi SC, Dodge RK, et al. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (greater than 50 chromosomes) acute lymphoblastic leukemia. Blood. 1989;73:1963-1967. (Pubitemid 19145131)
31. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989. (Pubitemid 26023779)
32. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258. (Pubitemid 26399172)